ClinicalTrials.gg

Program

YKST02

A development code.

Its studies are mostly in Multiple Myeloma, led by Excyte Biopharma.

Furthest: phase 2, since Jul 6, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Excyte Biopharma22 open or runningphase 2since Jul 6, 2026Aug 26, 2024Dec 31, 2026phase 1 · NCT06574568

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2024First study: phase 1 study in RecurrenceFirst studyNCT06574568 · 70 planned · China
  2. Jul 6, 2026Phase 2 study in RecurrencePhase 2 reachedNCT07695740 · 64 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in RecurrenceNCT06574568
  2. Dec 2030Primary completion: phase 2 study in RecurrenceNCT07695740

TargetBeta

CD3E →read by rule
“YKST02 is an investigational humanized bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells.”study text, by rule · the study

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07695740Recurrence · China2Not yet recruitingDec 203064
NCT06574568Recurrence · China1RecruitingDec 31, 202670

How it is read

Names in the registry

  • “YKST02”, 2 entries

Codes read as this program: YKST02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.